Clinical depression is a serious but common medical illness that adversely affects how people feel, think, and act. Antidepressant medication, psychotherapy, and changes in lifestyle are common initial recommendations for patients struggling with symptoms of clinical depression.
For patients who are coping with major depressive disorders, antidepressants can play an invaluable role. However, ones who have not responded to at least two antidepressant medications in their current depressive episode are considered to have treatment-resistant depression (TRD).
SPRAVATO™ (esketamine) CIII Nasal Spray, in conjunction with an oral antidepressant, is indicated for the treatment of TRD in adults. SPRAVATO™ is one of the first new types of depression medication in decades. If you have failed to response to other depression medicines, SPRAVATO™ may be an alternative for you.
What to Expect From an Esketamine SPRAVATO™ Appointment
The typical treatment schedule for SPRAVATO™ starts with appointments twice a week, then transitions into visits every one to two weeks. These sessions involve:
Induction and Preparation: If you need to drive to our clinic, you should plan a ride since you can’t operate machinery until the day after treatment. To reduce your risk of nausea or vomiting, avoid eating two hours before and drinking 30 minutes before your session.
Dosage: After your doctor takes your blood pressure, you will take SPRAVATO™ as a nasal spray with their supervision.
Observation: Your doctor will monitor you for side effects for two hours after your dosage.
Schedule a SPRAVATO™ Assessment Today
If you want to learn more about treatment-resistant depression, then please call Compassion Mental Health Services today at (724) 856-3588 or visit our facilities to arrange a confidential consultation. During our first appointment with you, we will evaluate your suitability for treatment.